CANCER:

Cholangiocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Biliary Tract Cancer (290)

Gallbladder Cancer (41)

Biliary Tract Cancer (290)

Gallbladder Cancer (41)

›

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification	Cholangiocarcinoma	FGFR2 amplification	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	ivosidenib Resistant: C4 – Case Studies NPJ Precis Oncol - 3 weeks (New C4) ivosidenib Resistant : C4 NPJ Precis Oncol - 3wk	ivosidenib Resistant: C4 – Case Studies NPJ Precis Oncol - 3 weeks ivosidenib Resistant : C4 NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM	Cholangiocarcinoma	FGFR2 M540_I541insMM	Cholangiocarcinoma	pemigatinib Sensitive: C4 – Case Studies Target Oncol - 3 weeks (New C4) pemigatinib Sensitive : C4 Target Oncol - 3wk	pemigatinib Sensitive: C4 – Case Studies Target Oncol - 3 weeks pemigatinib Sensitive : C4 Target Oncol - 3 weeks - (New C4)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B
HER-2 expression	Cholangiocarcinoma	HER-2 expression	Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	TT-00420 Sensitive: B - Late Trials TT-00420 Sensitive : B	TT-00420 Sensitive: B - Late Trials TT-00420 Sensitive : B
RET fusion	Cholangiocarcinoma	RET fusion	Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
BRCA2 mutation	Cholangiocarcinoma	BRCA2 mutation	Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Cholangiocarcinoma	BRCA1 mutation	Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
NTRK3 fusion	Cholangiocarcinoma	NTRK3 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Cholangiocarcinoma	NTRK2 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Cholangiocarcinoma	NTRK1 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
BRAF V600	Cholangiocarcinoma	BRAF V600	Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
MSI-H/dMMR	Cholangiocarcinoma	MSI-H/dMMR	Cholangiocarcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
BRAF V600E	Cholangiocarcinoma	BRAF V600E	Cholangiocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
NTRK2 fusion	Cholangiocarcinoma	NTRK2 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Cholangiocarcinoma	NTRK3 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK1 fusion	Cholangiocarcinoma	NTRK1 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
HER-2 overexpression	Cholangiocarcinoma	HER-2 overexpression	Cholangiocarcinoma	lapatinib Sensitive: C1 - Off-label lapatinib Sensitive : C1	lapatinib Sensitive: C1 - Off-label lapatinib Sensitive : C1
BRAF V600E	Cholangiocarcinoma	BRAF V600E	Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
FGFR2 translocation	Cholangiocarcinoma	FGFR2 translocation	Cholangiocarcinoma	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2
IDH2 mutation	Cholangiocarcinoma	IDH2 mutation	Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2
IDH1 R132C	Cholangiocarcinoma	IDH1 R132C	Cholangiocarcinoma	ivosidenib Sensitive: C2 – Inclusion Criteria ivosidenib Sensitive : C2	ivosidenib Sensitive: C2 – Inclusion Criteria ivosidenib Sensitive : C2

Cholangiocarcinoma

Associations(168)

Associations
(168)